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Abstract  
 
Purpose: Ovarian cancer remains a deadly malignancy because most patients develop 
recurrent disease that is resistant to chemotherapy. Organic anion-transporting 
polypeptides (OATPs) mediate the uptake of clinically important drugs thereby effecting 
intracellular drug accumulation. In this study, we investigated whether OATPs may also 
contribute to paclitaxel transport in estrogen-responsive and estrogen-independent 
ovarian carcinoma cell lines and tumor tissue.  
Methods: Expression of all 11 human OATPs in  human ovarian cancer tissue samples 
and in the ovarian carcinoma cell lines OVCAR-3 and SK-OV-3 was investigated using 
real-time RT-PCR. Kinetic analysis of paclitaxel uptake was characterized in both cell 
lines and in OATP-transfected Xenopus laevis oocytes. Cytotoxicity of paclitaxel in 
OVCAR-3, SK-OV-3 and OATP1B1- and OATP1B3-transfected SK-OV-3 cells was 
performed using the CellTiter-Glo assay.  
Results: OATP1B1 and OATP1B3 are active paclitaxel transporters in transfected X. 
laevis oocytes. Real-time RT-PCR analysis revealed expression of both OATPs in 
human ovarian cancer tissue specimens and in cancer cell lines. The higher mRNA 
levels for OATP1B1 and OATP1B3 found in SK-OV-3 cells correlated with higher initial 
uptake rates for paclitaxel. In addition, cytotoxicity studies with OATP1B1- and 
OATP1B3-transfected SK-OV-3 cells demonstrated lower IC50 values compared to cells 
transfected with the empty vector.  
Conclusions: Our results revealed OATP1B1 and OATP1B3 as high-affinity paclitaxel 
transporters expressed in ovarian cancer cell lines and tumor tissues, suggesting a role 
for these polypeptides in the disposition of paclitaxel during therapy.  
 
Keywords: ovarian cancer, paclitaxel, OATPs, PCR, SK-OV-3, OVCAR-3  
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1. Introduction 
Ovarian cancer is often diagnosed at an advanced stage because early symptoms are 
inconspicuous and reliable diagnostic biomarkers are not available [1]. This contributes 
to a poor 5-year overall survival rate of < 40% and a high death rate [2]. A combination 
of paclitaxel together with platinum derivatives is applied in standard chemotherapy 
after initial surgery on the tumor [3]. Although high response rates to this initial regimen 
are observed, a relapse is seen in two-thirds of patients. This is due to the rapid 
development of drug resistance, which is often caused by a reduced accumulation of 
the drug in cancer cells [4,5].  
 It is well established that overexpression of ATP-powered efflux pumps such as 
P-glycoprotein (P-gp) or MDR1, encoded by the ABCB1 gene, induce drug resistance to 
cytotoxic agents including paclitaxel [6]. Indeed, taxane resistance due to 
overexpression of P-glycoprotein (MDR1) has been shown in ovarian cancer [7]. 
Overexpression of the multidrug resistance-related proteins MRP2 (ABCC2), MRP3 
(ABCC3) and MRP7 (ABCC10) have been identified as paclitaxel-resistance factors in 
various cell lines and tumor tissues including HER-2-amplified breast carcinoma and 
non-small-cell lung cancer [8-10]. However, uptake mechanisms into tumor cells might 
be even more important than efflux transporters for the efficacy of anticancer drugs 
because they are determinants for intracellular drug concentration [11].  
One of the most important cellular drug uptake mechanisms in humans is via 
members of the organic anion-transporting polypeptide family (OATP) [12,13]. Official 
nomenclature differentiates between genes and protein, using the terms “SLCO” and 
“OATP,” respectively [14]. To facilitate readability and understanding of this manuscript, 
“OATP” is used for both genes and proteins. OATPs are expressed in a variety of 
tissues [15] and tumors [16,17], where they mediate the transport of endogenous and 
exogenous compounds, including drugs [12,13,18]. Studies have shown that uptake 
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transporters can confer sensitivity to anticancer agents [19-23], such as the OATP1B3 
substrate methotrexate [19]. This may be therapeutically important because expression 
of OATP varies greatly among tumor cell lines [24}.  
 Cellular uptake of paclitaxel is known to be facilitated by OATP1B3 in Xenopus 
laevis oocytes [25] and by Oatp1a/1b in mice, strongly affecting plasma levels and 
tissue distribution of paclitaxel [28]. Furthermore, it was shown that paclitaxel is also 
transported by the organic anion transporter 2 (OAT2; gene: SLC22A7) [26] expressed 
in humans, predominantly in the liver and kidney [27]. It is unknown whether OAT2 is 
also expressed in human cancer cells. As OATPs exhibit overlapping substrate 
specificity, we hypothesized that additional OATPs may also contribute to the uptake of 
paclitaxel. To gain further insight into the possible role of OATP transporters in the 
chemoresistance of ovarian cancer, we characterized the OATP mRNA expression 
profiles in estrogen-responsive OVCAR-3 [29] and the estrogen-independent SK-OV-3 
[30] ovarian cancer cell lines, and we investigated paclitaxel transport in X. laevis 
oocytes expressing all human OATPs. Our results demonstrate that paclitaxel uptake in 
OATP1B1 and OATP1B3 correlated with OATP1 and OATP3 mRNA expression, 
indicating a role for these transporters in tumor therapy. 
 
2. Material and methods 
 
2.1. Materials 
[3H]paclitaxel (740 GBq/mmol) was purchased from American Radiolabeled Chemicals 
(St. Louis, MO). The ovarian carcinoma cell lines OVCAR-3 and SK-OV-3 were 
originally obtained from the ATCC (Manassas, VA). Fetal Calf Serum (FCS) was 
obtained from Invitrogen (Carlsbad, CA). The ovarian carcinoma cell lines were 
maintained in phenol-red free RPMI-1640 medium supplemented with L-glutamine 
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(PAN-Biotech GmbH, Aidenbach, Germany), 10% FCS and 1% penicillin (10.000 U/ml) 
/ streptomycin (10 mg/ml) solution (Invitrogen) in a humidified atmosphere at 37 °C with 
5% CO2.  
 
2.2. Patient samples 
Frozen samples were obtained from patients undergoing routine surgery at the 
Department of Obstetrics and Gynecology, Medical University of Vienna. Informed 
consent was obtained from all patients, and permission for the study was obtained from 
the ethical committee of the institution. Pathological inspection revealed that all tumors 
were serous epithelial carcinomas. Patient characteristics, tumor staging and grading 
[31] are summarized in Table 1. Total RNA from healthy ovary tissue was obtained from 
Stratagene (La Jolla, CA).  
 
2.3. TaqMan® real-time RT-PCR 
Total RNA from OVCAR-3 and SK-OV-3 cancer cells and human ovarian cancer tissues 
was isolated using the RNeasy® Mini kit (Qiagen, Hilden, Germany), and the RNA was 
treated with RNase-free DNase (Qiagen) to remove genomic DNA. The concentration, 
purity and integrity of the RNA samples were determined using a Nanodrop ND-1000 
(Kisker-Biotech, Steinfurt, Germany) and agarose gel electrophoresis. 1 µg of total RNA 
was reverse-transcribed in 20-µl reactions using the High-Capacity cDNA RT kit 
(Applied Biosystems, Foster City, CA) with the provided random hexamer primers and 
RNase inhibitor (Applied Biosystems) according to the manufacturer’s instructions. 
TaqMan® Gene Expression Assays (Applied Biosystems) were purchased for all eleven 
human OATPs and four transporters from the ABC family (Table 2). Control assays for 
the ACTB (PN 4326315E) and HPRT1 (PN 4310890E) genes were also purchased from 
Applied Biosystems. Prefabricated primers and probes for the endogenous control 
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genes GAPDH and RPL13A were obtained from PrimerDesign (PrimerDesign Ltd., 
Southampton, UK). TaqMan® real-time RT-PCR was performed in an amplification 
mixture volume of 10 µl containing 5 µl 2x TaqMan® Gene Expression PCR Master Mix 
(Applied Biosystems), 0.5 µl of the appropriate Gene Expression Assay, 10 ng template 
cDNA diluted in 4 µl nuclease-free water and 0.5 µl nuclease-free water. Thermal 
cycling conditions were 2 min at 50 °C and 10 min a t 95 °C, followed by 40 cycles of 15 
s at 95 °C and 1 min at 60 °C on the 7900HT Sequenc e Detection System (Applied 
Biosystems) equipped with a 96-well fast cycling block. The results were imported into 
DataAssist™ 2.0 software (Applied Biosystems) for automated data analysis using the 
comparative Ct (∆∆Ct) method [32]. A normalization factor (NF) was calculated by 
averaging the Ct values of the four endogenous control genes ACTB, GAPDH, HPRT 
and RPL13A via the geometric mean. Relative quantities (RQ) for every sample were 
then calculated by the formula RQ = 2 (–∆Ct) / 2(–∆Ctreference), where ∆Ct = Average Ct – NF. 
The standard deviation (SD) was calculated for Ct values of the technical replicates and 
was used to calculate the RQMin and RQMax: 
RQMin = 2(–∆Ct – SD) / 2(–∆Ctreference)  
RQMax = 2(–∆Ct + SD) / 2(–∆Ctreference)  
according to the DataAssist™ v2.0 Software User Instructions (Applied Biosystems). 
 
2.4. Immunohistochemistry  
Immunohistochemistry staining experiments were done on 4-µM paraffin sections from 
ovarian cancer samples. Before application of antibodies, antigen retrieval was 
performed for 2 minutes in citrate buffer using a microwave oven (R-208, Sharp 
Electronics Europe, Vienna, Austria). Dilutions for primary antibodies were 1:100 for 
OATP1B1/1B3 (#BM5541, Acris, Herford, Germany), and incubations lasted for 16 hrs 
at 4°C, while the incubation with species-specific peroxidase-labeled IgG lasted for 1 
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hour. Thereafter, sections were processed for DAB visualization using the Envision+ 
System-HRP (DAB) kit (Dako, Glostrup, DK). Slides were mounted in Mowiol 4-88 (Carl 
Roth, Karlsruhe, Germany), and the OATP staining pattern was observed using an 
Axioplan 2 microscope (Carl Zeiss AG, Oberkochen, GE). 
 
2.5. Transient expression of OATP1B1 and OATP1B3 in SK-OV-3 cells 
OATP1B1 and OATP1B3 cDNA sequences (Kullak-Ublick et al. 2001) were inserted 
into the multiple cloning site of pCMV6-XL4, and the nucleotide sequence of the coding 
regions were confirmed by nucleic acid sequencing (MWG, Ebersberg, Germany). 
Exponential growth-phase SK-OV-3 cells were reverse transfected using FuGENE® HD 
Transfection Reagent (Roche, Basel, CH) at a lipid/DNA ratio of 3:1 (6 µl/2 µg). Briefly, 
2 µg of DNA was diluted into 100 µl of Opti-MEM (Invitrogen), 6 µl of FuGENE reagent 
was added, mixed and incubated for 15 min at room temperature. Subsequently, the 
transfection complex was transferred to one well of a six-well plate, and SK-OV-3 cells 
were added at 4 x 105 per well in 2 ml of RPMI-1640 medium supplemented with 10% 
FCS (without antibiotics). Based on low transfection efficiency, OATP1B1- and 
OATP1B3-transfected OVCAR-3 cells were not included in any further experiments.  
 
2.6. Cytotoxicity assay 
A total of 1000 cells/well (OVCAR-3, SK-OV-3, OATP1B1-transfected SK-OV-3 and 
OATP1B3-transfected SK-OV-3) were seeded in 96-well plates. After 48 h, cells were 
treated with graded concentrations of paclitaxel (0.5, 1.0, 2.0, 4.0, 6.0, 10.0 and 50.0 
nM) or 0.1% solvent dimethyl sulfoxide as control. Cell viability was measured after 48 h 
using the CellTiter-Glo® Assay (Promega, Madison, WI) and a Victor™ microplate 
reader (PerkinElmer, Waltham, MA). Corresponding IC50 values were calculated by non-
linear regression analysis using GraphPad Prism 5 software (GraphPad, La Jolla, CA). 
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2.7. Preparation of OATP cDNA for the expression in X. laevis oocytes 
The plasmids containing human full-length cDNA from OATP1B1 (pSPORT1) and 
OATP1B3 (pSPORT1) were originally cloned from a human liver cDNA library, and 
OATP2B1 (pCMV6-XL4) was cloned from a human brain cDNA library [33]. OATP1A2 
(pDRIVE, IHS1382-8428120), OATP2A1 (pOTB7, EHS1001-6793541) and OATP4C1 
(pENTR223.1, OHS4559-99620240) full-length cDNA clones were purchased from 
Open Biosystems (Thermo Fisher Scientific, Huntsville, AL). The lacking stop codon in 
the OATP4C1 clone was reconstructed by PCR using 0.5 mM dNTPs, 12.5 pmol of 
each primer, 0.5 U Hot Start Phusion® DNA polymerase (Finnzymes, Espoo, FI) and 1x 
HF buffer (Finnzymes) in a final volume of 25 µl. The following primer sequences were 
used (start codon in bold): forward: 5’-CC ACC ATG AAG AGC GC-3’ and reverse: 5’-
TCA CCC TTC TTT TAC TAT TTT GTT G-3’. Thermal cycling conditions were 98 °C for 
30 s, followed by 25 cycles of 98 °C for 10 s, 62 ° C for 20 s and 72 °C for 1 min on a 
MyCycler™ (Bio-Rad, Hercules, CA). The obtained full-length OATP4C1 PCR fragment 
was subcloned into the pJET1.2 vector (Fermentas, St.Leon-Rot, Germany) using blunt-
end cloning with a CloneJET PCR cloning kit (Fermentas) according to the 
manufacturer’s instructions. OATP1C1 (pBluescriptR, IRAKp961I0832Q) and OATP4A1 
(pOTB7, IRALp962P0734Q) plasmids were purchased from Imagenes (Berlin, 
Germany). To obtain full-length cDNA sequences of OATP3A1 and OATP5A1, we 
purchased total RNA from normal human ovaries (MVP™, Stratagene, La Jolla, CA). 
Total testis RNA (Clontech Laboratories, Inc., Mountain View, CA) for the cloning of 
OATP6A1 was kindly donated by Dr. D. Mechtcheriakova (Department of 
Pathophysiology, Medical University of Vienna, Austria). Reverse transcription was 
performed by preincubation of 0.4 µg total RNA with 0.5 µg oligo(dT) primers in a 
volume of 11 µl for 5 min at 65 °C. Subsequently, 9  µl of reverse transcription master 
mix was added, containing 0.5 mM of dNTPs (Fermentas), 20 U of RNaseOUT™ 
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(Invitrogen, Carlsbad, CA), 200 U of RevertAid™ H Minus M-MuLV reverse 
transcriptase (Fermentas) and 1x reaction buffer in a final volume of 20 µl. The mixture 
was incubated at 45 °C for 1 h followed by 70 °C fo r 10 min. The sequence of OATP6A1 
was amplified from 50 ng of testis cDNA, and the sequence of OATP3A1 and OATP5A1 
from 50 ng of ovary cDNA; the rest of the amplification cocktail consisted of 0.5 mM of 
dNTPs, 12.5 pmol of each primer, 0.75 µl DMSO, 0.5 U Hot Start Phusion® DNA 
polymerase (Finnzymes, Espoo, FI) and 1x GC buffer (Finnzymes) in a final volume of 
25 µl. Primer sequences were the following (start codons are in bold): OATP3A1, 
forward: 5’-A AGG ATG CAG GGG AAG AAG C-3’, reverse: 5’-GCC CTC CTT TAG 
TCA CTA TAA AAC GG-3’; OATP5A1, forward: 5’-TGA ATT CTA AGC GCC ATG GAC 
GAA-3’, reverse: 5’-TCT TCC ATT TTC AAG CTT CAG GAG G-3’; and OATP6A1, 
forward: 5’-A GCC ATG TTC GTA GGC GTC GC-3’, reverse: 5’- ATC ACA ATG ATG 
ATC CAG TTA CAA GTC AG-3’. PCR conditions for OATP3A1 were 98 °C for 30 s, 
followed by 40 cycles of 98 °C for 10 s, annealing at 68.5 °C for 20 s and extension at 
72 °C for 1 min on a Bio-Rad MyCycler™. The conditi ons for OATP5A1 and OATP6A1 
were identical except for annealing at 66 °C. The p urified cDNA was then cloned into 
the pJET1.2 vector using the CloneJET PCR cloning kit (Fermentas). Sequences of 
OATP3A1, OATP5A1 and OATP6A1 were checked by forward and reverse full-length 
sequencing (MWG) and compared to the appropriate reference sequences (OATP3A1 
transcript variant 1: NM_013272.3; OATP5A1: NM_030958.1; OATP6A1: 
NM_173488.3). In OATP3A1, we found a polymorphism for 1083G>C, resulting in the 
amino acid exchange of Glu294Asp. For OATP5A1, we detected an SNP at 1406C>G, 
leading to the amino acid exchange of Leu264Val. No polymorphisms were found in 
OATP6A1. 
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2.8. Linearization, template preparation, and in vitro transcription of OATP cRNA 
All plasmid inserts were verified for correct sequence and orientation by sequencing 
(MWG). For the in vitro synthesis of cRNA, the cDNA clone of OATP4A1 was linearized 
with BglII, and Mlul was used for the linearization of OATP1B1 and OATP1B3 plasmids. 
For OATP3A1, OATP4C1, OATP5A1 and OATP6A1, we used XbaI for linearization. 
OATP1C1 was linearized with Acc65I, and OATP2A1 was linearized with DraI. All 
restriction enzymes were obtained from Fermentas. After linearization, proteinase K and 
0.5% SDS treatment, plasmid DNA was purified by phenol/chloroform extraction and 
ethanol precipitation. OATP1A2 and OATP2B1 sequences were amplified from the 
plasmids using 0.5 mM of dNTPs, 12.5 pmol of each primer, 0.75 µl DMSO, 0.5 U Hot 
Start Phusion® DNA polymerase (Finnzymes) and 1x GC buffer (Finnzymes) in a final 
volume of 25 µl. Standard vector primers (M13) were used for amplification: forward: 5’- 
TGT AAA ACG ACG GCC AGT-3’ and reverse: 5’- CAG GAA ACA GCT ATG ACC-3’. 
Thermal cycling conditions were as follows: 98 °C f or 30 s, 25 cycles of 98 °C for 15 s, 
55 °C for 20 s and 72 °C for 1 min on a Bio-Rad MyC ycler™. The obtained OATP1A2 
and OATP2B1 PCR products were gel-purified and used as templates for in vitro 
transcription. 5’-capped cRNAs were transcribed in vitro using 1 µg of template DNA 
and either T7 or SP6 mMESSAGE mMACHINE® kit (Ambion, Austin, TX) according to 
the manufacturer’s instructions. Subsequently, the cRNAs were polyA-tailed using the 
polyA tailing kit (Ambion) according to the protocol. The polyA cRNA was then purified 
using the MEGAClear™ kit (Ambion). The concentration, purity and integrity of cRNA 
samples were determined on a Nanodrop ND-1000 (Kisker-Biotech) and by denaturing 
gel electrophoresis. 
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2.9. Paclitaxel transport studies in Xenopus laevis oocytes 
Preparation of stage V-VI oocytes from X. laevis was performed as previously described 
[34]. Briefly, X. laevis frogs (NASCO, USA) were anaesthetized by exposing them for 15 
min to a 0.2% solution of MS-222 (methane sulfonate salt of 3-aminobenzoic acid ethyl 
ester; Sandoz Company) before surgical removal of parts of the ovaries. Follicle 
membranes from isolated oocytes were enzymatically digested with 2 mg/ml 
collagenase (Type 1A, Sigma). One day after isolation, the oocytes were injected with 
either 10 - 50 nl of water to determine non-specific uptake of paclitaxel or water with 
approximately 200 ng/µl cRNA of each OATP. Injected oocytes were incubated in ND96 
buffer (90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM HEPES, pH 
adjusted to 7.4, supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin) at 
18 °C for 48 hours before performing transport expe riments with buffer exchange every 
day. Uptake studies were carried out in single oocytes using at least 12 oocytes per 
data point. Oocytes were washed three times with 3 ml substrate-free uptake buffer 
(100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 10 mM HEPES, pH adjusted to 
7.4 with TRIS) and incubated with 400 µl uptake buffer containing 20 nM [³H]paclitaxel 
and 1% ethanol at room temperature for the appropriate time points. To avoid unspecific 
binding of [³H]paclitaxel to the surfaces of laboratory plasticware, all solutions containing 
[³H]paclitaxel were manipulated using glassware. For kinetic analysis, the uptake of 
radiolabeled paclitaxel was measured over a range of concentrations, from 20 to 1180 
nM, using 60-min incubations within the linear component of uptake. Uptake was 
corrected for non-specific influx using water-injected oocytes from the same batch in 
each experiment. Uptake was stopped by the addition of 3 ml ice-cold uptake buffer, 
and oocytes were washed three times with buffer before being placed in scintillation 
vials for dissolution with 10% SDS overnight. Radioactivity was measured in a liquid 
scintillation counter (LS-6500; Beckman, California, USA).  
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2.10. Western blot analysis of OATP1B1 and 1B3 in X. laevis oocytes 
Oocyte protein expression and membrane localization of human OATP1B1 and 
OATP1B3 were confirmed by western blot using membrane and cytosolic protein 
fractions from OATP1B1- and OATP1B3-injected oocytes [35]. A total of 10 µg of 
protein was separated on 10% separating gels, blotted on PVDF membranes and 
probed using an antibody against OATP1B1/1B3 (#BM5541, Acris) diluted 1:250 in 
TBS-T (20 mM Tris, 145 mM NaCl, 0.05% Tween 20, pH 7.6) containing 5% milk 
powder [36]. On control blots, an antibody to α-tubulin (Sigma, T-5168) was diluted 
1:8000 in TBS-T containing 5% milk powder. The HRP-conjugated secondary antibody 
(#315-036-003, Jackson ImmunoResearch, Suffolk, UK) was used at a dilution of 
1:10000 in TBS-T.  
 
2.11. Transport experiments in OVCAR-3 and SK-OV-3 cells 
Cells that were 80-90% confluent were washed three times and incubated for 15 min 
(37 °C) in 12-well plates with 1 ml Krebs-Henseleit  buffer (KHB, 118 mM NaCl, 23.8 mM 
NaHCO3, 4.8 mM KCl, 1.0 mM KH2PO4, 1.2 mM MgSO4, 12.5 mM HEPES, 5.0 mM 
glucose, and 1.5 mM CaCl2, pH 7.4) (Hirano et al. 2004). Subsequently, cells were 
treated with 1 ml/well KHB containing 18.5 nM [3H] paclitaxel. Unlabeled paclitaxel was 
added to a final concentration of 5 µM. Uptake was measured after 1, 2, 4, 6 and 10 min 
or, alternatively, at graded concentrations (0.5, 1.0, 2.5, 5.0 and 10.0 µM paclitaxel) 
after 1 min of incubation, which had been determined to be within the linear range of 
uptake. Control studies were performed at 4 °C to d etermine temperature-insensitive 
paclitaxel accumulation. Paclitaxel transport was stopped by adding ice-cold KHB 
followed by three washes. The amount of paclitaxel in the cells was determined by first 
adding 300 µl 0.2 N NaOH to each well. After 12 h at 4 °C, 150 µl 0.4 N HCl and 4 ml 
Emulsifier-Safe™ scintillation cocktail (PerkinElmer) were added, and [3H]paclitaxel 
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uptake was measured in an LS6500 scintillation counter (Beckman Coulter, Fullerton, 
CA). Protein determination was performed using a BCA™ Protein Assay (Pierce, 
Rockford, IL), with bovine serum albumin as the standard. 
 
2.12. Data analysis 
For kinetic analysis, data were fitted to the Michaelis-Menten (hyperbolic) model. Kinetic 
parameters were estimated using Prism 5 software (GraphPad) for Michaelis-Menten 
kinetics: 
     V=Vmax·S/(Km+S),      
where V is the rate of reaction, Vmax is the maximum velocity, Km is the Michaelis 
constant, and S is the substrate concentration. Unless otherwise indicated, values are 
expressed as the mean ± SD of at least 12 individual oocytes per data point. Statistical 
differences from control values were evaluated using a Student’s t-test, and the level of 
statistical significance was set at P < 0.05. 
 
3. Results 
 
3.1. Expression of OATPs in human ovarian cancer specimens   
To assess the role of OATP transporters for paclitaxel uptake, we investigated the 
mRNA expression of all 11 human OATPs in a series of ovarian cancer tissue samples 
using TaqMan® real-time RT-PCR. Total RNA from normal ovary served as control. As 
shown in Table 3, mRNA of all 11 OATPs was observed in specimens of ten ovarian 
cancer patients at quite different levels (from 0.02-fold to 103-fold compared to the 
endogenous control gene HPRT1), whereas in normal ovaries, mRNA expression was 
confined to five OATP family members (OATP2A1, OATP2B1, OATP3A1, OATP4A1 
and OATP5A1). In normal ovary tissue, OATP1B1 and OATP1B3 mRNA expression 
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was below the detection limit, whereas OATP1B3 was clearly detected in 5/10 ovarian 
cancer specimens. Interestingly, three of the five OATP1B3-expressing samples also 
expressed OATP1B1. These data were confirmed by immunohistochemistry, 
demonstrating that protein levels of OATP1B1 and 1B3 correlate with mRNA expression 
in cancerous tissue (a representative tumor sample is shown in Fig. 1A). In line with 
real-time RT-PCR, no staining for these proteins was observed in noncancerous tissue 
(Fig. 1B). 
 
3.2. OATP mRNA expression in ovarian cancer cells  
We further investigated the mRNA expression profile of all human OATPs in the human 
ovarian carcinoma cell lines OVCAR-3 and SK-OV-3. Interestingly, expression of the 
liver-specific OATP1B3 mRNA was up to 204-fold higher in SK-OV-3 cells compared to 
OVCAR-3 cells (Table 4). Even more pronounced was the difference in OATP1B1 
expression, as this transporter was only found in SK-OV-3 cells. A different expression 
pattern was also observed for OATP2B1, which was 71-fold higher in SK-OV-3 cells, 
and for OATP5A1, which was 85-fold higher in the OVCAR-3 cell line. mRNA 
expression of OATP1A2, OATP2A1, OATP3A1, OATP4A1 and OATP4C1 was detected 
in OVCAR-3 and SK-OV-3, although the observed distribution was more balanced. 
Expression levels of OAT2 (previously identified as a potential paclitaxel transporter) 
[26], OATP1C1 and OATP6A1 were below the detection limit in both cell lines.  
 
3.3. Expression of paclitaxel efflux transporters in ovarian cancer cell lines 
Despite differing expression of OATP1B1 and OATP1B3, OVCAR-3 and SK-OV-3 cells 
displayed similar paclitaxel cytotoxicity. As overexpression of OATP increased the 
cytotoxicity of paclitaxel, the comparable sensitivity of naive OVCAR-3 cells to paclitaxel 
could be influenced by the different expression levels of efflux pumps. Therefore, we 
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further investigated the expression of four major paclitaxel efflux transporters in these 
two cell lines. We indeed observed up to 18-fold higher mRNA expression levels for 
MRP2 and MRP3 in SK-OV-3 cells (Table 5), suggesting a higher efflux of paclitaxel out 
of the cytoplasm into the cellular supernatant. MDR1 and MRP7 were similar in 
distribution between the two cell lines.  
 
3.4. Paclitaxel transport studies in X. laevis oocytes 
To investigate whether OATPs other than OATP1B3 contribute to paclitaxel uptake into 
OVCAR-3 and SK-OV-3 cells, uptake studies were performed for all 11 known human 
OATPs in X. laevis oocytes injected with cRNA coding for each of the OATP family 
members. Uptake of radiolabeled paclitaxel (20 nM for 60 min) in OATP1B1- and 
OATP1B3-expressing oocytes was significantly higher compared to the water-injected 
oocytes (5.3- and 3.9-fold, respectively; P < 0.0001). No other OATP favored paclitaxel 
uptake (Fig. 2). The time course of [³H]paclitaxel uptake by OATP1B1- and OATP1B3-
expressing oocytes was linear for up to 60 min (Figs. 3A and B). The kinetic constants 
for this uptake revealed saturable transport in OATP1B1-expressing oocytes, with a 
Vmax of 12.3 ± 0.4 fmol/oocyte/min and a Km value of 0.6 ± 0.04 µM. OATP1B3-injected 
oocytes showed a 2.4-fold higher Vmax for paclitaxel (30 ± 1.6 fmol/oocyte/min) and a 
2.7-fold higher KM value of 1.6 ± 0.13 µM compared to OATP1B1-injected oocytes (Figs. 
3C and D). OATP1B1 and OATP1B3 protein expression in X. laevis oocyte plasma 
membranes was also confirmed by western blot analysis (Figs. 3E and F). Involvement 
of both transporters for paclitaxel uptake was also confirmed in inhibition experiments 
by using the OATP1B1 and 1B3 substrate [³H]estrone-3-sulfate. Paclitaxel (2 µM) 
reduced intracellular accumulation of 20 nM [³H]estrone-3-sulfate in OATP1B1- and 
OATP1B3-expressing X. laevis oocytes to 44.1 ± 5.0 % and 63.0 ± 7.3 %, respectively, 
further confirming uptake by these transporters. 
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3.5. Transport of paclitaxel in ovarian cancer cell lines 
Based on the different expression levels of OATPs in OVCAR-3 and SK-OV-3 cells, we 
also expected altered intracellular paclitaxel levels. In both cell lines, uptake of 
paclitaxel was linear with time, up to 90 sec, with respect to 5 µM paclitaxel 
concentrations (data not shown). For kinetic analysis, an incubation time of 1 min was 
therefore chosen, showing typical Michaelis-Menten kinetics for the uptake of paclitaxel 
into the OVCAR-3 cells, with a Vmax of 517.5 ± 86.2 pmol/mg protein/min and a Km value 
of 17.2 ± 4.1 µM (Fig. 4A). Transport of paclitaxel into the SK-OV-3 cell line was far 
more pronounced, showing an uptake rate of 1660 ± 126 pmol/mg protein/min at a 
concentration of 10 µM. Because of the limited solubility of this drug in serum-containing 
cell culture medium, saturation kinetics could not be observed (Fig. 4B). 
 
3.6. Paclitaxel cytotoxicity in OATP1B1- and OATP1B3-transfected SK-OV-3 cells 
To investigate whether increased expression of either OATP1B1 or OATP1B3 could 
have an impact on paclitaxel cytotoxicity we tested the efficacy of paclitaxel in 
OATP1B1- and OATP1B3-transfected SK-OV-3 cells. As shown in Fig. 5, the IC50 was 
decreased to 2.8 ± 1.38 nM for paclitaxel in OATP1B1 cells and to 3.4 ± 1.27 nM in 
OATP1B3 cells (compared to 4.9 ± 1.35 nM in cells transfected with the empty vector).  
 
4. Discussion and conclusion 
 
In the present study, we elucidated the transcriptional expression for human OATPs in 
malignant and control ovarian tissue samples and in estrogen-responsive OVCAR-3 
and estrogen-independent SK-OV-3 ovarian cancer cell lines,  
By investigation of all 11 known OATPs by TaqMan® real-time RT-PCR, we found 
that OATP1B1, OATP1B3 and OATP2B1 were highly expressed in SK-OV-3 cells, 
whereas OATP1A2, OATP4C1 and OATP5A1 were primarily present in OVCAR-3 cells. 
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The two transporters OATP1C1 and OATP6A1 were not detectable in either cell line. It 
should be noted that expression of OAT2, which was previously shown to mediate the 
uptake of paclitaxel in X. laevis oocytes, was below the detection limit in both cell lines. 
Our data are consistent with the previous work of Okabe and coworkers, who showed 
similar differences of OATP expression in OVCAR-3 and SK-OV-3 cells [24]. However, 
contrary to their study, we were unable to confirm expression of OATP6A1 in the 
OVCAR-3 cell line.  
 To date, the only OATP that has been characterized as a high-affinity paclitaxel 
transporter [25] is OATP1B3. Uptake of paclitaxel was significantly reduced in the 
OATP1B3-expressing cell line HepG2 but not in OATP1B3-deficient PR-HepG2 cells by 
the OATP1B3 substrate and inhibitor bromosulfophtalein [37]. By systematically 
investigating the transport properties of paclitaxel for all 11 OATPs using the X. laevis 
oocytes expression system, we were able to identify OATP1B1 as an additional uptake 
protein for paclitaxel. Indirect involvement of OATP1B1 in taxane transport was reported 
by Gui and coworkers who showed inhibition of the OATP1B1 substrate estradiol-17β-
glucuronide by paclitaxel in stable transfected CHO cells [38]. An involvement of 
OATP1B1 in hepatic clearance of paclitaxel may explain the finding of a 
pharmacogenetic investigation of variants of the SLCO1B3 gene; Smith and coworkers 
found that differences in paclitaxel pharmacokinetics did not correlate with different 
OATP1B3 variants [39]. Nevertheless, one variant has recently been shown to influence 
the pharmacokinetics of mycophenolate [40].  
 Several ABC transporters have been shown to successfully expel paclitaxel from 
the cells. Importantly, it has been demonstrated that MDR1 and MRP2, as well as 
MRP3 and MRP7, mediate paclitaxel transport [7-10]. However, exposing SK-OV-3 
cells transiently overexpressing OATP1B1 and OATP1B3 to paclitaxel decreased their 
IC50, indicating that the sensitivity of the ovarian cancer cells to paclitaxel can be 
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modulated by OATP1B1/1B3 expression levels. Using TaqMan® real-time RT-PCR, we 
identified higher expression levels of MRP2 and MRP3 in SK-OV-3 cells, whereas 
differences of MDR1 and MRP7 mRNA expression were moderate. MRP2 and MRP3 
may therefore facilitate increased efflux of paclitaxel in SK-OV-3 cells.  
 Our data suggest that OATP1B1 might be an even more important determinant of 
paclitaxel uptake in ovarian cancer cells than OATP1B3, based on its lower Km value in 
X. laevis oocytes (0.6 µm vs. 1.6 µM). This Km is in the range of the mean plasma 
concentration in patients (0.85 ± 0.21 µM) after 24 h of infusion [41]. Our conclusion that 
paclitaxel could be a better substrate for OATP1B1than OATP1B3 is supported by very 
recent experiments of Gui and coworkers as they found that paclitaxel (2.5 µM) inhibited 
the uptake of the OATP1B1/1B3 substrate fluorescein-methotrexate by 93% in 
OATB1B1- but only by 53% in OATP1B3-expressing CHO cells [42]. Differences in 
estrogen-responsive and estrogen-independent ovarian cancer cell lines also suggest 
that alterations in mRNA expression levels may also be observed in tumor tissue 
samples from patients. It is known that the activity and the expression of transport 
proteins may vary greatly between individuals, as a function of genetic, environmental, 
and physiological factors. Indeed, we also demonstrated great differences in the 
expression of all 11 OATPs in 10 ovarian cancer specimens and one control tissue 
sample (Table 3). Among these polypeptides, expression of OATP1A2, OATP1B1, 
OATP1B3, OATP1C1, and OATP6A1 was found exclusively in the tumor samples but 
not in the control one.  
OATP1B1- and OATP1B3-mediated paclitaxel transport may be of clinical importance, 
as our data show for the first time that both transporters are also expressed in ovarian 
cancer specimens but not in control tissue. This expression is remarkable, since 
OATP1B1 and OATP1B3 are proposed to be expressed under normal conditions in liver 
only [14]. As the expression of both OATPs are positively regulated by the transcription 
 19 
factor HNF1α [43], any upregulation of HNF1α may subsequently increase OATP1B1 
and 1B3 levels. Indeed, Tomassetti and coworker demonstrated that vHNF1 (the variant 
isoform of the hepatocyte nuclear factor 1) is highly expressed in cancer tissue but not 
in normal ovarian epithelium [44].  
 OATP1B1 and OATP1B3 share a wide, overlapping substrate spectrum that 
includes HMG-CoA reductase inhibitors such as fluvastatin and pitavastatin, the 
antibiotic rifampicin and the endothelin receptor antagonist BQ123 [45]. The hepatic 
uptake rate of both transporters might be reduced by drug competition, resulting in 
increased blood levels. Therefore, inter-individual expression levels of OATP1B1 and 
OATP1B3 in the basolateral membrane of hepatocytes might be responsible for 
differences in the occurrence of toxic side effects such as neutropenia, neuropathy and 
cardiac effects during paclitaxel therapy. Such drug-drug interactions have been 
reported for the OATP1B1 and OATP1B3 substrates pravastatine and bosentan [46,47] 
when concomitantly administered with clarithromycin and cyclosporine or rifampicin, 
respectively.  
 In conclusion, we found that OATP1B1 and OATP1B3 are high affinity and active 
paclitaxel transporters in transfected X. laevis oocytes; this role may also apply for the 
uptake of this compound into human liver and ovarian cancer cells.  
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Legends to the Figures  
 
Fig. 1: Representative images of immunohistochemistry stainings using an 
OATP1B1/OATP1B3 specific antibody in ovarian tissue. In the ovarian carcinoma image 
of patient no. 2 (A) clear immunoreactivity with the antibody is seen, whereas no 
staining is observed in non-cancerous ovarian tissue (B). 
 
Fig. 2: Paclitaxel uptake in X. laevis oocytes. The uptake of [³H]paclitaxel was measured 
in X. laevis oocytes injected with human OATP cRNA after a 60-min incubation with 20 
nM [³H]paclitaxel. Data are given as the percent of controls ± SD of at least 12 oocytes 
per data point. OATPs showing significantly higher (***P < 0.001) uptake rates 
compared to water-injected oocytes (control) are marked with asterisks. 
 
Fig. 3: Time- and concentration-dependent uptake of paclitaxel by OATP1B1- and 
OATP1B3-expressing X. laevis oocytes. The time-dependent uptake of 20 nM 
[³H]paclitaxel was measured for OATP1B1 (A) and OATP1B3 (B) cRNA-injected 
oocytes. Water-injected X. laevis oocytes were included as a negative control. 
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Concentration-dependent paclitaxel uptake for OATP1B1- (C) and OATP1B3- 
expressing oocytes (D) was evaluated after an incubation time of 60 min with various 
paclitaxel concentrations ranging from 20 to 1180 nM. Data represent the mean ± SD of 
triplicate determinations. Protein expression of OATP1B1 (E) and 1B3 (F) in X. laevis 
oocytes was confirmed by western blot analysis of cRNA-injected (+) and water-injected 
(-) oocytes. 
 
Fig. 4: Time- and concentration-dependent uptake of paclitaxel in the ovarian cancer 
cell lines OVCAR-3 and SK-OV-3. The time-dependent uptake of 5 µM paclitaxel was 
measured in OVCAR-3 (A) and SK-OV-3 (B) cells at 1, 2, 4, 6 and 10 min. 
Concentration-dependent paclitaxel uptake in OVCAR-3 (C) and SK-OV-3 (D) cells was 
evaluated after an incubation time of 1 min at 4°C and 37°C with paclitaxel 
concentrations ranging from 0.5 to 10 µM. Kinetic constants were calculated by non-
linear least-square analysis. Data represent the mean ± SD of triplicate determinations. 
 
Fig. 5: Cytotoxic effect of paclitaxel. An ATP-based detection assay was used to assess 
paclitaxel cytotoxicity in with OATP1B1, OATP1B3, and empty vector transiently 
transfected SK-OV-3 cells. Eight measurements were performed for each dilution point 
(mean ± SD). 
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Table   1  
            
Tumor characteristics of patients 
  
              
Patient 
no. 
Age (y) at 
first 
diagnosis 
Number 
of 
relapses 
FIGOa Tb Nb Mb Grade 
                
1 62 1 IV 3b N1 M1 II 
2 40 3 IIIC 3c NX MX II 
3 47 6 IIC 2c N0 MO III 
4 39 2 IIIC 1c N1 MO II 
5 55 3 IIIC 3c NX MX III 
6 42 2 IIIC 3c NX MX IV 
7 52 2 IIA 2a NX M0 II 
8 64 2 IC 1c NX MO III 
9 57 2 IIIC 3c NX MX II 
10 44 2 IIIC 3c N1 MO III 
                
                
 
aAccording    to   the     International   Federation   of 
Gynecologists & Obstetricians  (FIGO);  bAccording  to  the  
International   Union   Against   Cancer   (UICC)   Tumor,   
Node Metastasis  (TNM) classification. 
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Table 2     
Overview of the applied gene expression assays (ABI) used for real-time RT-PCR analysis 
Protein 
name Assay IDa      Context sequence (5'→3') 
Accession                             
number 
     
OATP1A2 hs00245360_m1 ACCACCTTCAGATACATCTACCTCG NM_134431.2 
NM_021094.2 
OATP1B1 hs00272374_m1 ATTCCACATCATTTTCAAGGGTCTA NM_006446.3 
OATP1B3 hs00251986_m1 CTAACTTTTTGTTGGGAATCATAAC NM_019844.2 
OATP1C1 hs00213714_m1 CTCCTACCAAGGAACCAAACCTGTC NM_017435.3 
OATP2A1 hs00194554_m1 GCGCTTGCTGGCCTGGCTGCCATCT NM_005630.1 
OATP2B1 hs00200670_m1 CTGCCAGGAAGGGCAAGGACTCTCC NM_007256.2 
OATP3A1 hs00203184_m1 CTCCTCGCTCTATATAGGAATCCTG NM_013272.2 
OATP4A1 hs00249583_m1 CAGAGACCTGCCTCTCTCCATCTGG NM_016354.3 
OATP4C1 hs00698884_m1 TGGGAGAAAGCACTGATGTCACTGA NM_180991.4 
OATP5A1 hs00229597_m1 TCATTGGAAACTGGTGGAGTGGATT NM_030958.1 
OATP6A1 hs00542846_m1 CTACACTTGCAGGACTTGTTTTAAT NM_173488.3 
OAT2 hs00198527_m1 AGCCTCTGGTGGGTGCCTGAGTCTG NM_153320.2 
NM_006672.3                      
MDR1 hs00184500_m1 AGACATGACCAGGTATGCCTATTAT NM_000927.3 
MRP2 hs00166123_m1 CACCTCCAACAGGTGGCTTGCAATT NM_000392.3 
MRP3 hs00358656_m1 CAGCTGCTCAGCATCCTGATCAGGT NM_001144070.1 
NM_003786.3 
MRP7 hs00375716_m1 CCCAGCTCAGATCCCAGTTGGCTAT NM_033450.2 
aApplied Biosystems    
 
 
 
 
 
Table 3 
                                                                  
Expression levels of OATP mRNA in normal (N) and ovarian cancer specimensa 
Gene 
symbol N 1 2 3 4 5 6 7 8 9 10 
                                                                    
OATP1A2 ND 1,31 ±  0,11 0,08 ±  0,00 ND 0,02 ±  0,01 0,48 ±  0,02 0,13 ±  0,10 0,04 ±  0,00 0,04 ±  0,00 0,2 ±  0,0 ND 
OATP1B1 ND ND 2,33 ±  0,33 ND 1,19 ±  0,06 ND ND ND ND ND 0,4 ±  0,0 
OATP1B3 ND ND 1,27 ±  0,08 ND 2,18 ±  0,30 ND 0,06 ±  0,01 ND 0,04 ±  0,00 ND 1,1 ±  0,0 
OATP1C1 ND ND 0,04 ±  0,00 ND ND ND ND ND 0,10 ±  0,00 ND ND 
OATP2A1 4,35 ±  0,15 0,96 ±  0,30 3,03 ±  0,29 1,02 ±  0,14 1,03 ±  0,04 1,33 ±  0,25 3,05 ±  0,39 0,37 ±  0,01 2,02 ±  0,14 0,31 ±  0,01 0,42 ±  0,05 
OATP2B1 103 ±  2,02 1,13 ±  0,09 9,36 ±  1,14 4,90 ±  0,39 3,91 ±  0,27 7,23 ±  0,36 32,4 ±  6,86 3,32 ±  0,24 5,50 ±  0,57 4,19 ±  0,35 3,33 ±  0,29 
OATP3A1 1,88 ±  0,04 2,76 ±  0,12 1,23 ±  0,14 1,45 ±  0,16 1,25 ±  0,08 1,48 ±  0,07 1,34 ±  0,13 0,19 ±  0,01 2,03 ±  0,16 1,56 ±  0,13 1,54 ±  0,13 
OATP4A1 0,36 ±  0,01 0,22 ±  0,01 0,50 ±  0,03 0,31 ±  0,01 1,22 ±  0,05 0,07 ±  0,00 1,00 ±  0,28 0,02 ±  0,00 0,12 ±  0,01 0,06 ±  0,01 0,08 ±  0,00 
OATP4C1 0,02 ±  0,00 0,05 ±  0,02 0,05 ±  0,01 0,03 ±  0,01 0,04 ±  0,00 0,02 ±  0,01 0,67 ±  0,09 0,03 ±  0,00 0,15 ±  0,00 0,04 ±  0,00 ND 
OATP5A1 0,41 ±  0,06 1,34 ±  0,41 0,62 ±  0,08 0,12 ±  0,02 0,25 ±  0,04 0,63 ±  0,12 0,12 ±  0,06 0,09 ±  0,00 0,29 ±  0,03 0,13 ±  0,00 0,06 ±  0,01 
OATP6A1 ND 0,31 ±  0,10 0,03 ±  0,02 ND 0,03 ±  0,01 0,07 ±  0,02 ND ND ND 0,12 ±  0,00 0,05 ±  0,01 
                                                                    
amRNA expression level compared to reference gene (HPRT1); Maximum values are in bold; ND, transcripts were below the detection limit 
  
Table 4        
Expression levels of OATP mRNAs in ovarian cancer cell linesa 
Protein 
name 
OVCAR-3   SK-OV-3 
        
 RQ RQ-RQMin RQMax-RQ  RQ RQ-RQMin RQMax-RQ 
        
OATP1A2 1.00 0.1 0.06  0.07 0.00 0.00 
OATP1B1 ND ND ND  1.00 0.01 0.01 
OATP1B3 1.00 0.00 0.00  203.93 6.87 7.11 
OATP1C1 ND ND ND  ND ND ND 
OATP2A1 1.00 0.08 0.09  0.45 0.04 0.05 
OATP2B1 1.00 0.00 0.00  70.57 0.99 1.01 
OATP3A1 1.00 0.05 0.05  0.18 0.00 0.00 
OATP4A1 1.00 0.03 0.03  6.29 0.05 0.05 
OATP4C1 1.00 0.02 0.03  0.07 0.00 0.00 
OATP5A1 1.00 0.00 0.00  0.01 0.00 0.00 
OATP6A1 ND ND ND  ND ND ND 
 
amRNA expression levels relative to OVCAR-3; Maximum values are in bold; ND, 
transcripts were below the detection limit 
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Table 5        
Expression levels of ABC transporter mRNAs in ovarian cancer cell linesa 
Protein 
name 
OVCAR-3   SK-OV-3 
        
 RQ RQ-RQMin RQMax-RQ  RQ RQ-RQMin RQMax-RQ 
        
MDR1 1.00 0.00 0.00  1.73 0.02 0.02 
MRP2 1.00 0.01 0.01  18.31 1.15 1.23 
MRP3 1.00 0.04 0.05  5.30 0.28 0.29 
MRP7 1.00 0.01 0.02  0.93 0.00 0.00 
 
amRNA expression levels relative to OVCAR-3; Maximum values are in bold; ND, 
transcripts were below the detection limit 
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Fig. 1.  
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Fig. 2.  
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Fig. 3 
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Fig. 4. 
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Fig. 5.  
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